Ageism in healthcare is the discrimination against or differential treatment of patients based on their age, most often affecting older adults. It shows up in how providers communicate, what treatments they recommend, and even whether patients are included in the research that shapes their care. The World Health Organization estimates that one in two people worldwide hold ageist attitudes toward older people. In the United States alone, ageism costs an estimated $63 billion per year in excess healthcare spending, accounting for about one in every seven dollars spent on the eight most expensive health conditions among adults 60 and older.
How Ageism Shows Up in Clinical Settings
Ageism in healthcare operates on two levels: explicit and implicit. Explicit ageism involves conscious decisions to limit care based on a patient’s age. Implicit ageism is subtler and often unintentional. A provider might assume that depression is a normal part of aging rather than a treatable condition. They might skip a referral for physical therapy because they assume an 80-year-old won’t benefit. They might direct questions to an adult child instead of the patient sitting in front of them, bypassing the older person’s autonomy without ever recognizing they’ve done it.
In mental health care, ageist stereotypes push recommendations away from psychotherapy based on the assumption that older adults are resistant to change or uninterested in talk therapy. This leads to an overreliance on psychiatric medications in older patients, a pattern that’s well documented despite the fact that older adults face higher risks of adverse drug effects. The implicit belief that sadness or withdrawal is “just part of getting old” results in lower levels of care for depression and suicidality in this population.
The Problem With “Elderspeak”
One of the most common and least recognized forms of ageism is a communication pattern called elderspeak. This is the slow, simplified, overly sweet tone that some healthcare workers adopt with older patients, similar to the way adults talk to young children. It includes unnecessary offers of help (“I can do that for you if you’re comfortable with electronics”), unsolicited use of first names, and a general tone of condescension.
Elderspeak isn’t just annoying. It has measurable health consequences. Observational studies show that using elderspeak can double the odds of a patient resisting care, including physical resistance, emotional distress, and refusal to cooperate with essential tasks. In acute care settings, this resistance can lead to patients refusing vital monitoring, medication, post-surgical wound care, or physical activity needed to prevent complications.
The mechanism is straightforward: being patronized by an authority figure triggers a stress response. The body releases stress hormones that raise heart rate, blood pressure, and respiratory rate. For someone recovering from surgery or managing a complex medical condition, that physiological stress isn’t trivial. Research also shows that agitation caused by disrespectful communication increases the subjective experience of pain, sometimes requiring higher doses of pain medication. Over time, chronic exposure to elderspeak leads to decreased self-esteem, social withdrawal, and increased symptoms of depression and anxiety.
Exclusion From Clinical Trials
Perhaps the most structurally damaging form of ageism in healthcare is the systematic exclusion of older adults from the clinical trials that determine how diseases are treated. Older adults make up the majority of people with cancer, yet they remain a minority in the studies that test cancer drugs. A landmark analysis found that adults 65 and older accounted for two-thirds of patients with the four most common cancers (breast, lung, colorectal, and prostate) but only one-third of participants in clinical trials for those cancers. On average, trial participants were 6.5 years younger than the broader population affected by the disease.
The gap widens with age. Adults 70 and older represent 46% of the U.S. cancer population but only 20% of trial participants. For those 75 and older, the numbers are 31% of the cancer population versus 9% of trials. Most strikingly, patients over 80 account for about 16% of cancer cases but just 4% of the trial populations used in FDA drug registration decisions.
This matters because the safety and effectiveness data used to approve treatments come from younger, healthier patients. When those drugs are then prescribed to older adults, clinicians are essentially guessing about tolerability. Research confirms this concern: several newly approved cancer drugs turn out to be less well-tolerated in older patients than trial results suggested. Older patients experience more frequent adverse events than the younger populations the drugs were tested on.
Age-Based Resource Allocation
Ageism also surfaces in decisions about who gets access to scarce resources. During the COVID-19 pandemic, triage protocols came under intense scrutiny for how they handled age. While most ethical guidelines formally reject using age alone as a criterion for allocating resources like ICU beds, the reality is more complicated. Some countries, including Italy during peak crisis periods, alluded to imposing age restrictions under extreme scarcity. Switzerland’s guidelines explicitly used age alongside life expectancy, comorbidities, and frailty scores as exclusion criteria for ICU admission.
Several guidelines permit age as a tiebreaker when two patients have the same short-term prognosis, giving priority to the younger patient. The ethical reasoning behind this, sometimes called the “fair innings” argument, holds that a younger person has had fewer years of life and therefore deserves priority. But critics point out that this reasoning treats older lives as inherently less valuable, which is the definition of ageism.
The Financial and Health Toll
Ageism doesn’t just harm individual patients. It drives up costs across the entire system. A study published in The Gerontologist calculated the annual cost of ageism across the eight most expensive health conditions in Americans 60 and older. The total: $63 billion in a single year, representing 15.4% of all healthcare spending on those conditions. These costs stem from the ways age-related bias increases disease prevalence and worsens outcomes, creating a cycle where undertreated conditions become more expensive to manage.
At the individual level, the health consequences of ageism are well established. A large body of research shows that both institutional discrimination (like employment barriers) and interpersonal slights (like elderspeak) undermine self-esteem, mental health, cognitive functioning, and physical health in older adults. Internalized ageism, where older people absorb negative beliefs about aging and apply them to themselves, compounds these effects. People who hold more negative self-perceptions of aging tend to have worse health outcomes across nearly every measure studied.
What Actually Reduces Ageism
The evidence on reducing ageism in healthcare points to two approaches that consistently work: education and contact. Educational programs that teach healthcare workers about the aging process, challenge stereotypes, and build awareness of implicit bias have been shown in randomized controlled trials to significantly reduce ageist attitudes among nurses. A systematic review and meta-analysis confirmed that positive education about aging, combined with meaningful contact experiences with older adults, are the most effective interventions.
Successful programs have taken various forms: structured lecture series with discussion, intergenerational interaction programs, redesigned curricula in medical and nursing schools, cognitive-behavioral approaches, and even the strategic use of educational films and personal narratives from older adults. The common thread is replacing assumptions with actual knowledge about what aging does and doesn’t involve, and giving healthcare workers enough exposure to older patients as individuals that stereotypes become harder to maintain.